CoQ10 and D-ribose in Patients With Diastolic Heart Failure

The purpose of this study is to compare the clinical benefits of CoQ10 and D-ribose taken by
patients who have diastolic heart failure, or heart failure with preserved ejection fraction
(HFpEF).

Eligibility Criteria

Inclusion Criteria:

- Diagnosed with HFpEF within a 6-month period

- New York Heart Association (NYHA) Classification II-III HF

- Have left ventricular ejection fraction (EF) ≥ 50% documented by an echocardiogram

- Have a telephone or reliable phone contact

- Have their own means of transportation to the study site

Exclusion Criteria:

- Acute coronary syndrome in the past 12 weeks

- Significant valvular heart disease

- Severe cardiac fibrosis (galectin-3 level > 26 ng/ml)

- Constrictive pericardium

- Pulmonary fibrosis

- Congenital heart disease

- Hypertrophic or infiltrative cardiomyopathy

- Heart transplant

- Left ventricular assist device

- Heart failure (HF) associated hospital admission or emergency room visit within past
30 days

- Recent percutaneous coronary intervention

- Significant renal and/or hepatic dysfunction

- Severe cognitive impairment

- Consumption of any CoQ10 (ubiquinol) or D-ribose supplements

Principal Investigator

Janet Pierce, PhD

Study Contact

Amanda Thimmesch, athimmesch@kumc.edu, (913) 588-4336

Estimated Completion Date

Sunday, March 1, 2020

ClinicalTrials.gov #

NCT03133793
04/03/2018